CAP™ Ad cell line for adenoviral vector production
For adenoviral vector production that minimizes replication-competent adenovirus (RCA).
CAP™ Ad cell line for adenoviral vector production
For adenoviral vector production that minimizes replication-competent adenovirus (RCA).
CAP™ Ad cell line inquiries
CAPAD
On request
Stock on request
Price includes standard shipping and handling
Overview
The proprietary CAP™ Ad cell line, based on human suspension cells, is tailored for adenoviral vector production that minimizes replication-competent adenovirus (RCA). Suitable for applications ranging from research to industrial-scale production.
- Production without RCA: CAP™ Ad cells substantially mitigate the risk of generating replication-competent adenovirus (RCA).
- High-density growth: CAP™ Ad cells exhibit robust single-cell suspension growth to high densities in serum-free, chemically defined media, optimizing manufacturing efficiency.
- Compatibility with various bioreactors: CAP™ Ad cells seamlessly integrate with common bioreactors, offering flexibility and easy scalability to meet varying production demands.
- High-titer adenoviral vector production: CAP™ cells support the generation of adenoviral vectors with high titers, enhancing the overall productivity of large-scale manufacturing.
Product specifications
Showing 1 products
CAP™ Ad cell line inquiries
CAPAD
Stock on request
On request
Product availability is not guaranteed and subject to change.
